Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines

References

1. • Grundy S.M.
   • Stone N.J.
   • Bailey A.L.
   • et al.
   2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.
   Circulation. 2018; 10 (Cir0000000000000625)
   View in Article

   • Google Scholar
2. • Stone N.J.
   • Robinson J.G.
   • Lichtenstein A.H.
   • et al.
   2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
   J Am Coll Cardiol. 2014; 63: 2889-2934
   View in Article

   • Google Scholar
3. • Hulley S.B.
   • Rosenman R.H.
   • Bawol R.D.
   • Brand R.J.
   Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease.
   N Engl J Med. 1980; 302: 1383-1389
   View in Article

   • Google Scholar
4. • Assmann G.
   • Schulte H.
   • Funke H.
   • von Eckardstein A.
   The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
   Eur Heart J. 1998; 19: M8-M14
   View in Article

   • Google Scholar
5. • Austin M.A.
   • Hokanson J.E.
   • Edwards K.L.
   Hypertriglyceridemia as a cardiovascular risk factor.
   Am J Cardiol. 1998; 81: 7b-12b
   View in Article

   • Google Scholar
6. • Rana J.S.
   • Boekholdt S.M.
   • Kastelein J.J.
   • Shah P.K.
   The role of non-HDL cholesterol in risk stratification for coronary artery disease.
   Curr Atheroscler Rep. 2012; 14: 130-134
   View in Article

   • Google Scholar
7. • Fulcher J.
   • O'Connell R.
   • Voysey M.
   • et al.
   Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
   Lancet. 2015; 385: 1397-1405
   View in Article

   • Google Scholar
8. • Blum C.B.
   Type III Hyperlipoproteinemia: Still Worth Considering?.
   Prog Cardiovasc Dis. 2016; 59: 119-124
   View in Article

   • Google Scholar
9. • Brown M.S.
   • Goldstein J.L.
   A receptor-mediated pathway for cholesterol homeostasis.
   Science. 1986; 232: 34-47
   View in Article

   • Google Scholar
10. • Sniderman A.D.
    • St-Pierre A.C.
    • Cantin B.
    • Dagenais G.R.
    • Despres J.P.
    • Lamarche B.
    Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.
    Am J Cardiol. 2003; 91: 1173-1177
    View in Article

    • Google Scholar
11. • Sniderman A.D.
    • Williams K.
    • Contois J.H.
    • et al.
    A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.
    Circ Cardiovasc Qual Outcomes. 2011; 4: 337-345
    View in Article

    • Google Scholar
12. • Lawler P.R.
    • Akinkuolie A.O.
    • Ridker P.M.
    • et al.
    Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women.
    Clin Chem. 2017; 63: 870-879
    View in Article

    • Google Scholar
13. • Ballantyne C.M.
    • Raichlen J.S.
    • Cain V.A.
    Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    J Am Coll Cardiol. 2008; 52: 626-632
    View in Article

    • Google Scholar
14. • Lloyd-Jones D.M.
    • Braun L.T.
    • Ndumele C.E.
    • et al.
    Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease.
    Circulation. 2018; 10 (Cir0000000000000638)
    View in Article

    • Google Scholar
15. • Lloyd-Jones D.M.
    • Wilson P.W.
    • Larson M.G.
    • et al.
    Lifetime risk of coronary heart disease by cholesterol levels at selected ages.
    Arch Intern Med. 2003; 163: 1966-1972
    View in Article

    • Google Scholar
16. • Bachorik P.S.
    • Lovejoy K.L.
    • Carroll M.D.
    • Johnson C.L.
    Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III).
    Clin Chem. 1997; 43: 2364-2378
    View in Article

    • Google Scholar
17. • Sniderman A.
    • Tremblay A.
    • Bergeron J.
    • Gagne C.
    • Couture P.
    Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B.
    J Clin Lipidol. 2007; 1: 256-263
    View in Article

    • Google Scholar
18. • Hopkins P.N.
    • Brinton E.A.
    • Nanjee M.N.
    Hyperlipoproteinemia type 3: the forgotten phenotype.
    Curr Atheroscler Rep. 2014; 16: 440
    View in Article

    • Google Scholar
19. • Morganroth J.
    • Levy R.I.
    • Fredrickson D.S.
    The biochemical, clinical, and genetic features of type III hyperlipoproteinemia.
    Ann Intern Med. 1975; 82: 158-174
    View in Article

    • Google Scholar
20. • Boekholdt S.M.
    • Hovingh G.K.
    • Mora S.
    • et al.
    Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
    J Am Coll Cardiol. 2014; 64: 485-494
    View in Article

    • Google Scholar